Trademark: 90574267
Word
LATTICE
Status
Dead
Status Code
606
Status Date
Monday, March 25, 2024
Serial Number
90574267
Mark Type
4000
Filing Date
Thursday, March 11, 2021
Published for Opposition
Tuesday, June 28, 2022
Abandoned Date
Monday, March 25, 2024

Trademark Owner History
Ambry Genetics Corporation - Owner At Publication

Classifications
44 Providing genomic, imaging and pathology data being medical information and medical analyses based on collected clinical and research information in the field of cancer and other diseases for medical purposes; analysis of cells, tissues, gene expressions, gene sequences, genome annotation, transcriptome characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; preparation of reports relating to gene expressions, gene and genome sequences, genome interaction and annotation, transcriptome analysis and characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; medical assistance services in the nature of genetic and medical information provided to medical professionals from remote locations via the internet and global computer networks through the use of archived genome sequence information, medical images, diagnostic test results, and a data storage and retrieval system; medical genetic testing consultations provided via phone, online chat or videoconferencing; medical diagnostic testing, monitoring and reporting services; medical imaging services; medical information; medical screening; medical testing for diagnostic purposes; multi-disciplinary, integrative, genetic consultations for medical treatment purposes; providing a website featuring genetic and medical information; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the website that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; providing medical profiles and medical record analysis and assessments via a website that are designed to provide custom tailored outputs about recommended resources and treatments associated with a defined set of symptoms, concerns, genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; providing medical testing and medical consultations to individuals and their physicians to help them make health, wellness and nutritional changes in their daily living to improve health; providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms based on genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; provision of health care and medical services by health care professionals via the internet or telecommunication networks; remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; health assessment services, namely, providing assessment of risk of disease and providing health monitoring of individuals all through use of genome sequencing analysis and reporting, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; all for medical treatment and diagnostic purposes
42 Consulting services relating to scientific and medical research concerning genomic, imaging, pathology and clinical data; designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine; clinical research in the fields of de-risking clinical trial or study designs, clinical trials simulations and clinical endpoint selection; clinical research, namely, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic, imaging, pathology and clinical data; medical and scientific research, namely, conducting laboratory testing for clinical trials of pharmaceuticals and medical devices in humans; health care services, namely, medical laboratory services and clinical scientific laboratory services for testing clinical specimens for the purpose of providing information for medical research, clinical trials, and pre-clinical investigations; clinical research in the fields of patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses; clinical research, namely, accessing and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; consulting, consultancy, and consulting services related to clinical trials or studies, namely, designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine, de-risking clinical trial or study designs, conducting clinical trials simulations, clinical endpoint selection, analyzing preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; consulting, consultancy, and consulting services related to clinical trials or studies, namely, conducting patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; conducting drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses in the nature of medical research, and pharmaceutical development, in the fields of omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, all related to the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; medical research in the nature of disease diagnoses and treatment determination, selection, and identification of cells, proteins, small molecules, and nucleotides in a sample for scientific, research, and technological purposes, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and services all in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation for others

Trademark Events
Mar 25, 2024
Abandonment Notice E-Mailed - No Use Statement Filed
Mar 25, 2024
Abandonment - No Use Statement Filed
Oct 26, 2023
Assigned To Examiner
Jun 15, 2023
Notice Of Approval Of Extension Request E-Mailed
Jun 13, 2023
Sou Extension 2 Granted
Jun 13, 2023
Sou Extension 2 Filed
Jun 13, 2023
Sou Teas Extension Received
Jan 26, 2023
Notice Of Approval Of Extension Request E-Mailed
Jan 24, 2023
Sou Extension 1 Granted
Jan 24, 2023
Sou Extension 1 Filed
Jan 24, 2023
Sou Teas Extension Received
Aug 23, 2022
Noa E-Mailed - Sou Required From Applicant
Jun 28, 2022
Official Gazette Publication Confirmation E-Mailed
Jun 28, 2022
Published For Opposition
Jun 23, 2022
Assignment Of Ownership Not Updated Automatically
Jun 8, 2022
Notification Of Notice Of Publication E-Mailed
May 25, 2022
Approved For Pub - Principal Register
May 25, 2022
Examiner's Amendment Entered
May 25, 2022
Notification Of Examiners Amendment E-Mailed
May 25, 2022
Examiners Amendment E-Mailed
May 25, 2022
Examiners Amendment -Written
May 9, 2022
Notification Of Final Refusal Emailed
May 9, 2022
Final Refusal E-Mailed
May 9, 2022
Final Refusal Written
Apr 5, 2022
Teas/Email Correspondence Entered
Apr 4, 2022
Correspondence Received In Law Office
Apr 4, 2022
Teas Response To Office Action Received
Oct 7, 2021
Notification Of Non-Final Action E-Mailed
Oct 7, 2021
Non-Final Action E-Mailed
Oct 7, 2021
Non-Final Action Written
Oct 6, 2021
Assigned To Examiner
Jun 11, 2021
New Application Office Supplied Data Entered
Mar 15, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24